Search for content and authors

Synthesis and antiproliferative activity in vitro of (4-substituted-2-butynylthio)quinolines

Wojciech Mól 1Małgorzata Matyja 1Adam Naczyński 1Katarzyna Szczaurska-Nowak 2Magdalena Milczarek 2Joanna Wietrzyk 2Stanisław Boryczka 1

1. Medical University of Silesia, Department of Organic Chemistry, Jagiellonska 4, Sosnowiec 41-200, Poland
2. Polish Academy of Sciences, Institute of Immunology and Experimental Therapy (IITD), Rudolfa Weigla 12, Wrocław 53-114, Poland


Acetylenic derivatives are an important class of compounds since many of them display interesting biological activities and possess anticancer, antibacterial, antimicrobial, HIV-inhibitory properties. The synthetic methods for their preparation are of interest especially with regard to the synthesis of enediyne antibiotics [1-3]. The natural enediynes are the most potent of anticancer agents discovered, some members of which are three order of magnitude more potent than other anticancer drugs but their clinical use has been limited because of their toxicity and modest selectivity for cancer cells. It has prompted several research groups to design, prepare, and test new simplified, fully synthetic acetylenic analogues, characterized by a similar mode of action [1-4].

As an extension of our work on the development of anticancer drugs, we synthesized the series of new 3,4-disubstituted thioquinolines 1 possessing propargyl, 2-butynyl, 4-bromo(chloro)-2-butynyl and 4-substituted-2-butynyl groups with the aim to obtain more information about the influence of substituents on antiproliferative activity in this class of compounds.


The obtained compounds were tested for their antiproliferative activity in vitro against the cells of human (colon SW 707, leukemia CCRF/CEM, breast T 47D) and murine (leukemia P388, melanoma B 16) cancer cell lines. The most active compounds have the ID50 values ranging from 0,43 to 4,00 mg/ml comparable to that of referential cis-platin.

[1]. K.Nicolaou, W.-M. Dai, Angew. Chem. Int. Ed. Engl., 30, 1387 (1991).

[2]. G.B.Jones, F.S.Found, Curr. Pharm. Design., 8, 2415 (2002).

[3]. S. Boryczka, W.Mól, A.Jowsa, Wiad. Chem., 61, 275 (2007).

[4]. W.Mól, A.Naczyński, S.Boryczka, J.Wietrzyk, A.Opolski, Pharmazie, 61, 742 (2006).

This study was supported by Polish Ministry of Science and Higher Education (Grant No. N405 036 31/2655).


Legal notice
  • Legal notice:

Related papers

Presentation: Oral at VI Multidyscyplinarna Konferencja Nauki o Leku, by Stanisław Boryczka
See On-line Journal of VI Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2008-03-18 16:19
Revised:   2009-06-07 00:48